Trial Profile
An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery (NadiHN)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NadiHN
- 17 Jan 2018 New trial record